HOOK — Hookipa Pharma Income Statement
0.000.00%
Last trade - 00:00- $10.25m
- -$29.43m
- $43.95m
Annual income statement for Hookipa Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 19.6 | 18.4 | 14.2 | 20.1 | 43.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 72.9 | 100 | 87.4 | 118 | 95.4 |
| Operating Profit | -53.3 | -81.7 | -73.2 | -97.7 | -51.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -44.1 | -75.7 | -64.7 | -81.2 | -43.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -44.1 | -75.7 | -64.9 | -81.6 | -43.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -44.1 | -75.7 | -64.9 | -81.6 | -43.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -44.1 | -75.7 | -64.9 | -81.6 | -43.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -16.9 | -23 | -9.91 | -7.75 | -3.12 |